Please assess the completion status of the following clinical trial:

Trial Title: Incobotulinum Toxin for the Treatment of Trigeminal Neuralgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:Inclusion Criteria~* Age 18 - 75 yrs~* Male or non-pregnant/non-lactating female~* Subjects must have a mean attack frequency of at least 3 episodes/day of 4/10 pain~* Use of adequate birth-control measures as determined by investigator for females of child-bearing potential~* Diagnosis of Classical trigeminal neuralgia (TN) using International Classification of Headache Disorders (ICHD-2) criteria (see Appendix A in Protocol)~* Subjects have given written informed consent prior to entering study~* Subjects on a stable dose of concomitant preventive medications for treatment of TN for at least 4 weeks prior to study entry and throughout the 12 week observation period~* Subjects who require rescue analgesic medication during the study will be allowed to use their current (pre-study) opioid and/or non opioid analgesics as clinically indicated (e.g., non-steroidal anti-inflammatory drugs (NSAIDs), acetaminophen, cyclooxygenase-2 (COX-2) inhibitors, topical analgesics).~* Subjects will be prohibited from initiating any therapy with a new preventive medication throughout the remainder of the study.~* Subject must be willing and able to abstain from initiating an alternative therapy (e.g., acupuncture, massage or physical therapy) for pain relief during the study.~(NOTE: subjects who are currently using alternative therapy for pain relief can be enrolled if they are willing and able to maintain such therapy stable throughout the study.)~-~Exclusion Criteria:Exclusion Criteria~* Symptomatic TN~* Serious hepatic, respiratory, hematologic, cardiovascular or renal condition~* Neurologic pain other than TN, with the exception of occasional migraine or tension-type headaches. (\<4 headaches per month; \< 10 headache days/month)~* Psychiatric or medical condition that might compromise participation in study, as determined by the investigator~* Administration of any investigational drug within 30 days prior to screening~* History of substance abuse/alcoholism

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Incobotulinumtoxina (Type: ACTIVE_COMPARATOR): Xeomin 25-100 units injected to chosen area one time.
- Placebo Comparator (Type: PLACEBO_COMPARATOR): Placebo Comparator is 1-2 ml normal saline solution injected to chosen area one time.

Based on this trial design, predict the completion outcome and termination type (if applicable).